Skip to main content
Top
Published in: Dermatology and Therapy 2/2021

Open Access 01-04-2021 | Alopecia Areata | Original Research

Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study

Authors: Randall Winnette, Susan Martin, Nimanee Harris, Linda S. Deal

Published in: Dermatology and Therapy | Issue 2/2021

Login to get access

Abstract

Introduction

Although alopecia areata (AA) profoundly impacts patients’ physical appearance, emotional state, and daily activities, no treatment approved for AA currently exists. Patient-reported outcome (PRO) instruments currently used to capture patients’ AA experiences do not meet the requirements to support claims of treatment benefit as described in the US Food and Drug Administration’s 2009 PRO guidance. Our objective was to explore the consequences and priority treatment outcomes among individuals with AA and develop a PRO measure consistent with regulatory requirements that assesses these priorities and represents clinical benefit from the AA patient perspective.

Methods

Targeted literature and instrument reviews informed an initial concept set. Concept elicitation interviews with 20 adults with AA confirmed the relevance and importance of the initial concepts, identified additional relevant concepts, and informed an AA consequence model. Thematic analysis yielded a draft item pool, which was evaluated through two iterative rounds of cognitive debriefing interviews with 16 patients with AA (9 adults; 7 adolescents).

Results

Hair loss was the primary consequence of importance to patients with AA. Patients emphasized the need to differentiate hair loss by location: scalp, eyebrows, eyelashes, and body. Consequences of AA include difficulty conducting daily activities, particularly outdoor activities and exercise, and emotional impacts such as sadness, frustration, and negative self-image. Following cognitive debriefing interviews, 11 items were included to form the Alopecia Areata Patient Priority Outcome (AAPPO), assessing AA-related symptoms and impacts over the past week.

Conclusions

The AAPPO is a novel, content-valid PRO that captures the consequences of AA of the highest priority to patients.
Literature
1.
go back to reference Skogberg G, Jackson S, Åstrand A. Mechanisms of tolerance and potential therapeutic interventions in alopecia areata. Pharmacol Ther. 2017;179:102–10.CrossRef Skogberg G, Jackson S, Åstrand A. Mechanisms of tolerance and potential therapeutic interventions in alopecia areata. Pharmacol Ther. 2017;179:102–10.CrossRef
2.
go back to reference Montgomery K, White C, Thompson A. A mixed methods survey of social anxiety, anxiety, depression and wig use in alopecia. BMJ Open. 2017;7:e015468.CrossRef Montgomery K, White C, Thompson A. A mixed methods survey of social anxiety, anxiety, depression and wig use in alopecia. BMJ Open. 2017;7:e015468.CrossRef
8.
go back to reference Food and Drug Administration. The voice of the patient: a series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative: Alopecia Areata. Meeting date: September 11, 2017; report date: 2018. https://www.fda.gov/media/112100/download. Accessed 21 February 2020. Food and Drug Administration. The voice of the patient: a series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative: Alopecia Areata. Meeting date: September 11, 2017; report date: 2018. https://​www.​fda.​gov/​media/​112100/​download. Accessed 21 February 2020.
9.
go back to reference Food and Drug Administration. The voice of the patient: a series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative: Alopecia Areata. Transcript date: September 11, 2017. https://www.fda.gov/media/110943/download. Accessed 21 February 2020. Food and Drug Administration. The voice of the patient: a series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative: Alopecia Areata. Transcript date: September 11, 2017. https://​www.​fda.​gov/​media/​110943/​download. Accessed 21 February 2020.
10.
go back to reference Willis GB. Cognitive interviewing: a tool for improving questionnaire design. Thousand Oaks: Sage Publications; 2001. Willis GB. Cognitive interviewing: a tool for improving questionnaire design. Thousand Oaks: Sage Publications; 2001.
11.
go back to reference Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.CrossRef Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.CrossRef
12.
go back to reference Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433–40.CrossRef Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433–40.CrossRef
13.
go back to reference Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105–10. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105–10.
14.
go back to reference Nijsten TE, Sampogna F, Chren MM, Abeni DD. Testing and reducing skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol. 2006;126(6):1244–50.CrossRef Nijsten TE, Sampogna F, Chren MM, Abeni DD. Testing and reducing skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol. 2006;126(6):1244–50.CrossRef
15.
go back to reference Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.
16.
go back to reference Ware JE Jr. The SF-36 health survey. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven. 1996. Ware JE Jr. The SF-36 health survey. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven. 1996.
17.
go back to reference Mendoza TR, Osei JS, Shi Q, Duvic M. Development of the alopecia areata symptom impact scale. J Investig Dermatol Symp Proc. 2013;16(1):S51–2.CrossRef Mendoza TR, Osei JS, Shi Q, Duvic M. Development of the alopecia areata symptom impact scale. J Investig Dermatol Symp Proc. 2013;16(1):S51–2.CrossRef
18.
go back to reference Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur J Dermatol. 2012;22(4):531–6. Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur J Dermatol. 2012;22(4):531–6.
19.
go back to reference Fabbrocini G, Panariello L, De Vita V, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol. 2013;27(3):e276–81.CrossRef Fabbrocini G, Panariello L, De Vita V, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol. 2013;27(3):e276–81.CrossRef
Metadata
Title
Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study
Authors
Randall Winnette
Susan Martin
Nimanee Harris
Linda S. Deal
Publication date
01-04-2021
Publisher
Springer Healthcare
Keyword
Alopecia Areata
Published in
Dermatology and Therapy / Issue 2/2021
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-021-00508-w

Other articles of this Issue 2/2021

Dermatology and Therapy 2/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.